Dr. Konstantin Zhernosekov

Chief Scientific Officer / Managing Director ITM Medical Isotopes & ITM Oncologics

Dr. Konstantin Zhernosekov joined ITM in 2012 and serves as Chief Scientific Officer of ITM and Managing Director of ITM Medical Isotopes and ITM Oncologics GmbH. He oversees research, regulatory affairs, and translational imaging strategies, and drives ITM’s innovative radiopharmaceutical pipeline.

From 2006 to 2010, during his postdoctoral tenure at the Technical University of Munich (TUM), Konstantin was already collaborating with ITM to develop industrial-scale radiochemistry methods for no-carrier-added radionuclides like Lutetium-177 and Gallium-68. Before joining ITM in April 2012, he continued his academic carrier as a lead of a research group at the Paul Scherrer Institute in Switzerland, focusing on the application of novel medical radioisotopes for cancer treatment. 

At ITM, he initially served as a Vice President, leading the EMA marketing approval of ITM’s first product, EndolucinBeta. From 2012 to 2016, Konstantin was Managing Director of ITM’s then subsidiary OncoBeta GmbH, where he secured CE certification for the Re-188-SCT skin cancer therapy device. In 2016, he played a key role in the setup of ITM Oncologics GmbH, launching the company’s pivotal Phase III clinical trial, COMPETE.

With a PhD in Chemistry from Johannes Gutenberg University Mainz, Germany, and extensive expertise in radiopharmaceutical innovation, Konstantin continues to shape ITM’s vision to transform cancer care worldwide.